A. Marantz

Phase II study of gemcitabine, 5-fluorouracil, and leucovorin in patients with pancreatic cancer.

L. Fein, D. Lewi, S. Jovtis, 2001, Seminars in oncology.

Prognosis of metastatic giant cell tumor of bone in the pre-denosumab era. A systematic review and a meta-analysis

D. Lewi, Ariel Esteban Bardach, A. Marantz, 2018, Japanese journal of clinical oncology.

The Role of Prenylamine in the Prevention of Adriamycin-Induced Cardiotoxicity. A Review of Experimental and Clinical Findings

A. Boveris, J. Milei, S. Llesuy, 1988, The Journal of international medical research.

Prevention of adriamycin-induced cardiotoxicity by prenylamine: a pilot double blind study.

J. Milei, A. Vazquez, A. Marantz, 1987, Cancer drug delivery.

A controlled trial of the effect of 4-hydroxypyrazolopyrimidine (allopurinol) on the toxicity of a single bolus dose of 5-fluorouracil.

P. Woolley, P. Schein, F. Smith, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of gemcitabine (GEM), 5-Fluoruracil (5-FU) and leucovorin (LV) in advanced pancreatic cancer (PC)

L. Fein, D. Lewi, S. Jovtis, 1999 .

PEGYLATED LIPOSOMAL DOXORUBICIN IN AIDS-RELATED KAPOSI'S SARCOMA

D. Lewi, P. Politi, A. Marantz, 1998 .

Sequential methotrexate, 5-fluorouracil (high-dose), and doxorubicin for advanced gastric cancer.

M. Bader, C. Blajman, A. Marantz, 1986, Cancer treatment reports.

Neoadjuvant chemotherapy with cisplatin, ifosfamide and 5-fluorouracil in the treatment of locally advanced cervical cancer.

G. Cecchin, D. Lewi, A. Marantz, 2000, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.